|
|
Volumn 6, Issue 2, 2016, Pages 115-116
|
|
PI3K inhibitor improves PFS in BELLE-2 trial
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BUPARLISIB;
EVEROLIMUS;
FULVESTRANT;
PALBOCICLIB;
PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR;
AMINOPYRIDINE DERIVATIVE;
ANTINEOPLASTIC AGENT;
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
ESTRADIOL;
MORPHOLINE DERIVATIVE;
NVP-BKM120;
PHOSPHATIDYLINOSITOL 3 KINASE;
ESTROGEN RECEPTOR POSITIVE BREAST CANCER;
HUMAN;
HYPERGLYCEMIA;
LIVER DYSFUNCTION;
MOOD DISORDER;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
PROGESTERONE RECEPTOR POSITIVE BREAST CANCER;
PROGRESSION FREE SURVIVAL;
RASH;
ANALOGS AND DERIVATIVES;
ANTAGONISTS AND INHIBITORS;
BREAST NEOPLASMS;
DISEASE FREE SURVIVAL;
DRUG EFFECTS;
DRUG RESISTANCE;
FEMALE;
GENETICS;
ORGANIZATION;
TREATMENT OUTCOME;
AMINOPYRIDINES;
ANTINEOPLASTIC AGENTS, HORMONAL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BREAST NEOPLASMS;
CLINICAL TRIALS, PHASE III AS TOPIC;
CONGRESSES AS TOPIC;
DISEASE-FREE SURVIVAL;
DRUG RESISTANCE, NEOPLASM;
ESTRADIOL;
FEMALE;
HUMANS;
MORPHOLINES;
PHOSPHATIDYLINOSITOL 3-KINASE;
TREATMENT OUTCOME;
|
|
EID: 84957055746
PISSN: 21598274
EISSN: 21598290
Source Type: Journal
DOI: 10.1158/2159-8290.CD-NB2015-176 Document Type: Note |
|
Times cited : (15)
|
|
References (0)
|